Data availability
The datasets used or analyzed during the current study are available from the corresponding author on reasonable request.
References
Mhandire K, Saggu K, Buxbaum NP. Immunometabolic therapeutic targets of graft-versus-host disease (GvHD). Metabolites. 2021;11. https://doi.org/10.3390/metabo11110736.
Ciurea SO, Al Malki MM, Kongtim P, Zou J, Aung FM, Rondon G, et al. Treatment of allosensitized patients receiving allogeneic transplantation. Blood Adv. 2021;5:4031–43. https://doi.org/10.1182/bloodadvances.2021004862.
Yoshihara S, Maruya E, Taniguchi K, Kaida K, Kato R, Inoue T, et al. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transpl. 2012;47:508–15. https://doi.org/10.1038/bmt.2011.131.
Ciurea SO, Cao K, Fernandez-Vina M, Kongtim P, Malki MA, Fuchs E, et al. The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation. Bone Marrow Transpl. 2018;53:521–34. https://doi.org/10.1038/s41409-017-0062-8.
Sicard A, Phares TW, Yu H, Fan R, Baldwin WM 3rd, Fairchild RL, et al. The spleen is the major source of antidonor antibody-secreting cells in murine heart allograft recipients. Am J Transpl. 2012;12:1708–19. https://doi.org/10.1111/j.1600-6143.2012.04009.x.
Richard C, Romón I, Perez-Encinas M, Baro J, Rabuñal MJ, Mazorra F, et al. Splenectomy for poor graft function after allogeneic bone marrow transplantation in patients with chronic myeloid leukemia. Leukemia. 1996;10:1615–8.
Orandi BJ, Lonze BE, Jackson A, Terezakis S, Kraus ES, Alachkar N, et al. Splenic irradiation for the treatment of severe antibody-mediated rejection. Am J Transpl. 2016;16:3041–5. https://doi.org/10.1111/ajt.13882.
Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transpl. 2006;38:291–7. https://doi.org/10.1038/sj.bmt.1705445.
Zhu L, Guo Z, Sa R, Guo H, Li J, Chen G. Case report: splenic irradiation for the treatment of chronic active antibody-mediated rejection in kidney allograft recipients with de novo donor-specific antibodies. Front Immunol. 2021;12:661614. https://doi.org/10.3389/fimmu.2021.661614.
Yamamoto T, Watarai Y, Takeda A, Tsujita M, Hiramitsu T, Goto N, et al. De novo anti-HLA DSA characteristics and subclinical antibody-mediated kidney allograft injury. Transplantation. 2016;100:2194–202. https://doi.org/10.1097/tp.0000000000001012.
McManigle W, Youssef A, Sarantopoulos S. B cells in chronic graft-versus-host disease. Hum Immunol. 2019;80:393–9. https://doi.org/10.1016/j.humimm.2019.03.003.
Weinmann M, Becker G, Einsele H, Bamberg M. Clinical indications and biological mechanisms of splenic irradiation in autoimmune diseases. Strahlenther Onkol. 2001;177:105–11. https://doi.org/10.1007/pl00002384.
Acknowledgements
We would like to thank Dr. Jing Li, Dr Silu Liu for the collection of the initial data. We would also like to thank the department of radiotherapy of the first affiliated hospital of Soochow University, which provides the equipment and facilities for radiation therapy for the patients.
Funding
This work was supported by the National Natural Science Foundation of China (Grant Nos. 82170222, 81974001, and 82073337); the Jiangsu Natural Science Foundation (BK20211070); The Key Disease Program of Suzhou (LCZX202101); National Science and Technology Major Project (2017ZX09304021); National Key R&D Program of China (2019YFC0840604, 2017YFA0104502); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Jiangsu Medical Outstanding Talents Project (JCRCA2016002); and Jiangsu Provincial Key Research and Development Program (BE2019670); Jiangsu Provincial Key Medical Center (YXZXA2016002).
Author information
Authors and Affiliations
Contributions
SZ, XM, and CM contributed to the accrual and treatment of patients, data acquisition, interpretation and analysis. DW, XW, and SQ performed the research and designed this study. XW contributed to study concept and protocol development, oversight of study conduct, and data interpretation and analysis. Q Zhu, Q Zhao and ZT contributed to data interpretation and analysis. SZ wrote this paper. All authors drafted and reviewed the manuscript, approved the final version and decided to publish this report, and they all vouch for data accuracy and completeness.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval and consent to participate
The experimental protocol was established, according to the ethical guidelines of the Helsinki Declaration and was approved by the Human Ethics Committee of the Medical Ethics Committee of the First Affiliated Hospital of Soochow University. Written informed consent was obtained from individual or guardian participants.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Zhou, S., Ma, X., Ma, C. et al. Splenic irradiation combined with plasmapheresis and rituximab: a new option reducing donor-specific antibody in haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplant 58, 226–228 (2023). https://doi.org/10.1038/s41409-022-01868-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-022-01868-3
- Springer Nature Limited